A stent for the treatment of cardiovascular diseases, when the earliest foreign products dominated the world, the unit price was as high as nearly 30,000 yuan. With the introduction of domestically produced brackets, the latest bidding price has dropped below 10,000 yuan. The gospel brought about by the localization of medical devices to the health of Chinese residents has received much attention in recent years. Recently, the annual reports disclosed by many domestic listed companies indicate that the localization of medical devices has further accelerated. Thanks to policy support and focus on innovation, domestically produced medical devices and imported medical devices have been in the stage of running in some areas, and the role of “import substitution†will become more apparent in the future. The annual report has repeatedly revealed that the medical device industry has more points to watch. Hong Kong-listed companies and domestic leading medical device companies Shanghai Weichuang Medical Group recently released financial reports showing that in 2016, the company's operating income was nearly 390 million US dollars, excluding the impact of exchange rate, an increase of 6.6%. The profit was $15.1 million, compared to a loss of $11.4 million in the same period last year. "New policies, new opportunities, and the pursuit of safety quality by all parties are conducive to the development of innovative, large-scale and international enterprises," said Chang Zhaohua, chairman and CEO of MicroPort Medical. According to the financial report, in 2016, the core business of minimally invasive cardiovascular intervention products reached US$138 million, up 11.8% year-on-year. It is worth mentioning that the sales revenue of the third generation drug stent “Fire Eagle†independently researched and developed by MicroPort has increased by 127%, of which the overseas market growth rate reached 212%. The orthopaedic device business that MicroPort has acquired through international acquisitions has also maintained steady growth. In particular, China's orthopaedic business has developed rapidly, and the sales of joint products have increased by 32%, far higher than the market average. In addition to the listed companies that focus on medical devices, Fosun Pharma, which is developing its health business, is also very promising. According to the financial report, in 2016, Fosun’s medical device and diagnostic business achieved sales revenue of 2.653 billion yuan, a year-on-year increase of 18.23%, which was higher than 14.83% of the pharmaceutical manufacturing sector. It is worth mentioning that the Da Vinci surgical robot exclusively distributed by Fosun Pharma in China has about 19,000 operations in China and Hong Kong in 2016, an increase of 54% compared with 2015. It is the great prospect of seeing the medical device industry. In September last year, Fosun Pharma announced that it has established a joint venture with Da Vinci's robotic robotics company, Intuition Medical Devices, in Shanghai to develop, produce and market early diagnosis of lung cancer. And therapeutic products to promote the promotion and development of Fosun's medical device business with its leading position in the field of minimally invasive surgery robots. Earbuds Design Hearing Aid Earbuds Design Hearing Aid Shenzhen Sunshine Technology Co.,Ltd , https://www.szyatwin.com